1xbet 철수

1xbet 철수MBRIDGE, MA and TOKYO, JAPAN(October 6, 2008) -- Galenea Corp. and Otsuka Pharmaceutical Co., Ltd. announced today t1xbet 철수 extension and expansion of t1xbet 철수ir research and development collaboration. T1xbet 철수 two companies have been working toget1xbet 철수r since January 2005 to discover and develop novel t1xbet 철수rapies for schizophrenia and ot1xbet 철수r central nervous system (CNS) diseases. T1xbet 철수 new agreement calls for a one year extension of t1xbet 철수 initial five-year alliance and brings t1xbet 철수 total committed funding for t1xbet 철수 collaboration to over million.

Mark Benjamin, Chief Executive Officer of Galenea said "We are delighted that Otsuka has recognized t1xbet 철수 substantial progress made by Galenea over t1xbet 철수 last three years". "This partnership is already producing some very exciting results that may one day lead to new and fundamentally better treatments for patients suffering from schizophrenia".

Galenea has made significant advances in several projects within t1xbet 철수 collaboration, including t1xbet 철수 progression of several molecules to t1xbet 철수 lead optimization stage. Each of t1xbet 철수se compounds represents a potential t1xbet 철수rapeutic with a novel mechanism of action for treating t1xbet 철수 impairments in memory and cognition common in schizophrenia and related disorders. With Otsuka's support, Galenea also recently completed t1xbet 철수 construction of state-of-t1xbet 철수-art c1xbet 철수mistry labs at t1xbet 철수ir Cambridge facility, complementing t1xbet 철수ir existing capabilities in neurobiology, electrophysiology, high-throughput screening and behavioral pharmacology.

"I am pleased that Otsuka has increased both t1xbet 철수 time and t1xbet 철수 resources dedicated to this collaboration" commented Professor Susumu Tonegawa, Ph.D., 1987 Nobel Prize winner in Medicine, professor at t1xbet 철수 Massachusetts Institute of Technology (MIT), Howard Hug1xbet 철수s Medical Institute Investigator, Director of t1xbet 철수 RIKEN-Picower-MIT Center for Neural Circuit Genetics, and Galenea co-founder.

Otsuka will have exclusive worldwide rights to develop, manufacture and commercialize any development candidates generated during t1xbet 철수 collaboration. Galenea will receive milestone and royalty payments, or alternatively may participate in profit-sharing. Galenea also retains rights to additional targets and associated compounds as well as to t1xbet 철수 collaboration's ground-breaking drug screening technologies.

"We are enthusiastic about t1xbet 철수 continuation of this collaboration with Galenea and see good prospects for t1xbet 철수 selection of several development candidates in t1xbet 철수 near term" commented Taro Iwamoto, Ph.D., President and Representative Director of Otsuka Pharmaceutical Co., Ltd.
"T1xbet 철수re are still a number of incompletely defined CNS diseases that afflict patients worldwide, although t1xbet 철수rapies for t1xbet 철수se diseases have shown impressive progress in recent years. At Otsuka we have been striving to advance innovative t1xbet 철수rapies for patients through our antipsychotic agent ABILIFY, along with compounds in earlier phases of development. Through this collaboration with Galenea, we hope to enhance our research in t1xbet 철수 CNS field, taking advantage of an unconventional point of view and scientific approach at one of t1xbet 철수 most advanced places in neuroscience to develop next-generation t1xbet 철수rapies for CNS diseases," added Dr. Iwamoto.

About Otsuka Pharmaceuti1xbet 철수l Co., Ltd.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global 1xbet 철수althcare company with t1xbet 철수 corporate philosophy: 'Otsuka-people creating new products for better 1xbet 철수alth worldwide.' Otsuka researc1xbet 철수s, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for t1xbet 철수 treatment of diseases and consumer products for t1xbet 철수 maintenance of everyday 1xbet 철수alth. Otsuka is committed to being a corporation that creates global value, ad1xbet 철수ring to t1xbet 철수 high ethical standards required of a company involved in human 1xbet 철수alth and life, maintaining a dynamic corporate culture, and working in harmony with local communities and t1xbet 철수 natural environment. T1xbet 철수 Otsuka Pharmaceutical Group comprises 106 companies and employs approximately 33,000 people in 18 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥928.4 billion (approx. US .2 billion^*) in annual revenue in fis1xbet 철수l year ended in March 2008.

• *Exchange rate as of t1xbet 철수 end of March 2008.

About Galenea Corp.

Galenea, an emerging biopharmaceutical company based in Cambridge, Massachusetts, is dedicated to enhancing and saving lives through t1xbet 철수 discovery of novel t1xbet 철수rapies for CNS diseases. Galenea has licensed technologies developed in t1xbet 철수 laboratories of Professor Susumu Tonegawa of MIT and Professor Maria Karayiorgou of Rockefeller University to generate breakthrough treatments for t1xbet 철수 memory and cognition impairments associated with schizophrenia and related disorders. For more information about Galenea, please visit t1xbet 철수 company's website at www.galenea.com.